NCT00646035View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis

PHASE3CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

November 30, 2002

Conditions
End Stage Renal Disease
Interventions
DRUG

paricalcitol capsules

baseline iPTH/60

Trial Locations (24)

11501

Mineola

20007

Washington D.C.

29425

Charleston

31405

Savannah

33603

Tampa

33919

Fort Myers

37205

Nashville

38105

Memphis

44195

Cleveland

45206

Cincinnati

45220

Cincinnati

46202

Indianapolis

60153

Maywood

60201

Evanston

63110

St Louis

70112

New Orleans

77030

Houston

79430

Lubbock

80230

Denver

89102

Las Vegas

90095

Los Angeles

97210

Portland

30-501

Krakow

Unknown

Krakow

Sponsors

Lead Sponsor

Abbott
All Listed Sponsors
lead

Abbott

INDUSTRY

NCT00646035 - A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis | Biotech Hunter | Biotech Hunter